Lv3
270 积分 2023-08-30 加入
POS1160 A PHASE IB, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUSLY ADMINISTERED MOSUNETUZUMAB IN PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
2小时前
待确认
Mechanistic Projection of First‐in‐Human Dose for Bispecific Immunomodulatory P‐Cadherin LP‐DART: An Integrated PK/PD Modeling Approach
8小时前
已完结
Mechanistic Projection of First‐in‐Human Dose for Bispecific Immunomodulatory P‐Cadherin LP‐DART: An Integrated PK/PD Modeling Approach
8小时前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
8小时前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
10天前
已完结
Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma
17天前
已完结
Risankizumab for Ulcerative Colitis
27天前
已完结
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
1个月前
已完结
Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study
1个月前
已完结
Asthma and COPD: Similarities and Differences in the Pathophysiology, Diagnosis and Therapy
1个月前
已完结
皖公网安备34019202002308
